KR20170111640A - Composition Containing Monolaurin for Preventing Biofilm Formation of Streptococcus mutans - Google Patents
Composition Containing Monolaurin for Preventing Biofilm Formation of Streptococcus mutans Download PDFInfo
- Publication number
- KR20170111640A KR20170111640A KR1020160037496A KR20160037496A KR20170111640A KR 20170111640 A KR20170111640 A KR 20170111640A KR 1020160037496 A KR1020160037496 A KR 1020160037496A KR 20160037496 A KR20160037496 A KR 20160037496A KR 20170111640 A KR20170111640 A KR 20170111640A
- Authority
- KR
- South Korea
- Prior art keywords
- monolaurin
- present
- composition
- biofilm
- streptococcus mutans
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 241000194019 Streptococcus mutans Species 0.000 title claims abstract description 38
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 title claims description 55
- 230000032770 biofilm formation Effects 0.000 title description 21
- 208000002925 dental caries Diseases 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000000845 anti-microbial effect Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 241000589652 Xanthomonas oryzae Species 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 239000002609 medium Substances 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- -1 human serum albumin) Chemical compound 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 235000010419 agar Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000007621 bhi medium Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UVJAGAXWVHGYRW-ALCCZGGFSA-N (5z)-4-bromo-5-(bromomethylidene)-3-butylfuran-2-one Chemical compound CCCCC1=C(Br)\C(=C\Br)OC1=O UVJAGAXWVHGYRW-ALCCZGGFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CBLLOWCZXVHDNK-UHFFFAOYSA-N 1,2,3-trihydroxypentadecan-4-one Chemical compound CCCCCCCCCCCC(=O)C(O)C(O)CO CBLLOWCZXVHDNK-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 241001519550 Delisea Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241001175500 Diospyros ebenum Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- VGADRJOQALVEDC-UHFFFAOYSA-N fimbrolide Natural products CCCCC1=C(Br)C(=C(Br)Br)OC1=O VGADRJOQALVEDC-UHFFFAOYSA-N 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000003032 phytopathogenic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000004059 quinone derivatives Chemical class 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/192—Monoglycerides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Agronomy & Crop Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 흰잎마름병 원인균인 Xanthomonas oryzae와 치아우식 원인균인 Streptococcus mutans의 바이오필름 형성을 방지하는 모노라우린을 함유하는 조성물에 관한 것으로, 본 발명의 조성물을 이용하면, Streptococcus mutans에 의한 치아우식과 Xanthomonas oryzae에 의한 벼 흰잎마름병을 효과적으로 예방할 수 있다.The present invention relates to a method for producing Xanthomonas oryzae and Streptococcus mutans which is a causative organism of dental caries. The composition of the present invention can effectively prevent dental caries caused by Streptococcus mutans and Xanthomonas oryzae , Can be prevented.
Description
본 발명은 바이오필름 형성 방지용 조성물에 관한 것으로, 더욱 자세하게는 치아우식 원인균인 Streptococcus mutans의 바이오필름 형성을 방지하는 모노라우린을 함유하는 조성물에 관한 것이다.The present invention relates to a composition for inhibiting the formation of a biofilm, and more particularly to a composition containing monolaurin that prevents biofilm formation of Streptococcus mutans , a causative agent of dental caries.
바이오필름은 미생물에 의하여 형성된 막 모양 구조체이며, 표면에 연결된 미생물 세포층으로 이루어진 잘 구성된 미생물계로 복잡한 구조적 기능적 특징을 가지고 있다. 생체막은 미생물의 대사 과정에 영향을 주는 물리 화학적 구배를 갖는다. 바이오필름을 형성하는 세포는 부유세포보다 항생제에 대한 저항성이 1,000배 이상 높으며, 바이오필름 형성은 여러 질병의 발병(pathogenesis)에 중요한 역할을 한다(Rasmussen and Givskov 2006). Biofilm is a membrane-like structure formed by microorganisms, and is a well-organized microbial system composed of microbial cell layers connected to the surface. Biomembranes have physicochemical gradients that affect the metabolism of microorganisms. Cells that form biofilms are more than 1,000 times more resistant to antibiotics than floating cells, and biofilm formation plays an important role in the pathogenesis of many diseases (Rasmussen and Givskov 2006).
한편, 장 출혈성 병원성 대장균은 식품의 오염이나 출혈성 대장염 즉, 용혈성 요독증후군를 이끌 수 있는 혈변으로 인해 장관 내에 침투하는 인체 병원균이다. 최근 들어, 이들 병원균이 일반 부유상태가 아닌 표면에 부착하여 생존할 수 있다는 것이 알려지게 되었다. 따라서 잠재적인 병원균에 의해 생성되는 바이오필름(biofilm)은 고질적이고 재발되는 감염의 중요한 원인으로 생각되며, 특히 의료 장비의 표면이나 인체 내부의 유치 장치에서도 바이오필름을 형성하고 견디는 능력 때문이라고 생각된다. 최근에 바이오필름에 관련된 조사가 늘어나고 있는 가운데, 대부분은 근본적인 바이오필름의 예방, 조절, 근절 등을 목적으로 하고 있다. 그동안 아주 소수의 연구만이 병원성 대장균 계통을 포함하여 E. coli 등에 의해 형성되는 바이오필름을 억제하는, 천연 물질을 밝히고 특성을 기술하였다. 해조류 Delisea pulchra로부터 생성된 (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone과, 가봉의 흑단나무인 Diospyros dendo로부터 생성되는 우르솔릭산(ursolic acid, 3-beta-hydroxy-urs-12-en-28-oic acid), 비병원성 대장균군에 의해 생성되는 그룹 캡슐모양의 다당류 등의 화합물이, 바이오필름의 형성을 유의적으로 억제하였다. 그러나 이 화합물들의 독성과, 물에 잘 녹지 않는 특성 때문에 식품 및 약학산업에의 이용에 한계가 있다.On the other hand, enterohemorrhagic pathogenic Escherichia coli is a human pathogen that penetrates into the intestinal tract due to contamination of food or hemorrhagic colitis, that is, blood which can lead to a hemolytic uraemic reaction. Recently, it has become known that these pathogens can adhere to and survive on surfaces that are not normally suspended. Thus, biofilm produced by potential pathogens is considered to be an important cause of chronic and recurrent infections, especially due to the ability to form and sustain biofilms on the surfaces of medical devices and in the human body. With the recent surge in biofilm research, most are aimed at prevention, control, and eradication of fundamental biofilms. Meanwhile, the very study only a small number of pathogenic E. coli strains containing the E. coli And the like, which are inhibited by the biofilm formed by the biofilm. Algae Delisea (5Z) -4-bromo-5- (bromomethylene) -3-butyl-2 (5H) -furanone produced from the pulchra and the ebony tree Diospyros Compounds such as ursolic acid (3-beta-hydroxy-urs-12-en-28-oic acid) produced from dendo and group capsular polysaccharides produced by non-pathogenic Escherichia coli Respectively. However, the toxicity of these compounds and their poor water solubility limit their use in the food and pharmaceutical industries.
또한, 치아우식균으로 알려져 있는 Streptococcus mutans는 Gram-positive균으로, 입 속에서 음식을 예비 소화시키는 세균이나, 당류를 접하게 되면 이를 발효시켜 산을 생성시키고, 끈적끈적한 물질을 생산하여 균주와 함께 바이오 필름 즉, 플라그를 만들어 이 세균이 치아에 달라붙는 것을 도와준다. 이때, 세균의 신진 대사 산물로 만들어진 산(acid)이 치아 표면을 공격하여 에나멜질에 구멍을 내며, 충치를 유발하는 것으로 알려져 있다.In addition, Streptococcus mutans, which is known as a phytopathogenic fungus, is a Gram-positive bacterium that pre-digests food in the mouth, or when it comes into contact with saccharides, it fermentes it to produce acids and produces sticky substances, A film, a plaque, helps the bacteria stick to the teeth. At this time, it is known that the acid, which is made of the metabolite of bacteria, attacks the tooth surface and punctures the enamel, causing tooth decay.
또한, Xanthomonas oryzae가 생산하는 바이오필름은 벼에 감염되었을 때, 도관의 통로를 막게 되고, 이를 통해 영양분의 전달이나 물의 전달이 원활하지 않아서 잎이 죽기 시작하여 벼가 죽거나 살아남더라도 쌀을 정상적으로 생산할 수 없게 되는 흰잎마름병을 일으키게 된다. In addition, Xanthomonas When biofilms produced by oryzae are infected with rice, the pathway of the conduit is blocked, whereby the transfer of nutrients and the transfer of water are not smooth, so that the leaf begins to die and the rice is killed or survived, It causes a blight.
모노라우린(Monolaurin)은 글리세롤 모노라우레이트, 글리세릴 라우레이트 또는 1-라우로일-글리세롤로 알려진 모노글리세라이드(Monoglyceride)이다. 모노라우린은 글리세롤 및 라우르산으로부터 형성된 모노 에스테르로서 코코넛 오일에서 발견된 천연물질이다. 한국공개특허공보 제2015-0113979호는 바실러스 코아굴란스로부터 부분적으로 정제된 세포외 대사물질 생산물을 생산하는 방법에 관한 것으로, 모노라우린을 개시하고 있으나 이는 방부제 블렌드 조성에 해당한다.Monolaurin is a monoglyceride known as glycerol monolaurate, glyceryl laurate or 1-lauroyl-glycerol. Monolaurin is a monoester formed from glycerol and lauric acid, a natural substance found in coconut oil. Korean Patent Laid-Open Publication No. 2015-0113979 discloses a method for producing a partially purified extracellular metabolite product from Bacillus coagulans, which discloses monolaurin, which corresponds to a preservative blend composition.
이에, 본 발명자들은 인체에 독성이 없이 안정하고 세포의 성장을 저해하여 약제저항성을 나타내지 않으면서, 바이오필름 억제 효과가 뛰어난 천연물질을 개발하고자 예의 노력한 결과, 모노라우린이 벼의 흰잎마름병 원인균인 Xanthomonas oryzae와 치아우식 원인균인 Streptococcus mutans의 바이오필름 형성을 효과적으로 억제하는 것을 확인하고, 본 발명을 완성하게 되었다. Accordingly, the present inventors have made intensive efforts to develop a natural substance which is stable without toxicity on the human body, inhibits growth of cells and exhibits drug resistance, and has excellent biofilm inhibiting effect. As a result, it has been found that monolaurin- Xanthomonas oryzae and Streptococcus mutans , a causative organism of dental caries, and thus completed the present invention.
본 발명의 목적은 각 균주에 대한 바이오필름 억제능이 우수한 모노라우린을 함유하는 바이오필름 형성 방지용 조성물을 제공하는데 있다.It is an object of the present invention to provide a composition for inhibiting the formation of a biofilm containing monolaurin having excellent biofilm inhibiting ability for each strain.
본 발명의 다른 목적은 Streptococcus mutans 균주의 바이오필름 억제능이 우수한 모노라우린을 함유하는 치아우식증 예방 또는 치료용 조성물을 제공하는데 있다.Another object of the present invention is to provide a method for producing Streptococcus mutans The present invention provides a composition for preventing or treating dental caries comprising monolaurin having excellent biofilm inhibiting ability.
본 발명의 또 다른 목적은 Streptococcus mutans 균주의 바이오필름 억제능이 우수한 모노라우린을 함유하는 치아우식증 예방용 의약외품을 제공하는데 있다.Another object of the present invention is to provide a method for producing Streptococcus mutans Which is superior in inhibiting the biofilm of a strain, and a monolaurin-containing quinone derivative for inhibiting dental caries.
본 발명의 또 다른 목적은 Streptococcus mutans 균주의 바이오필름 억제능이 우수한 모노라우린을 함유하는 치아우식증 예방용 건강기능식품을 제공하는데 있다.Another object of the present invention is to provide a method for producing Streptococcus mutans The present invention provides a health functional food for preventing dental caries which contains monolaurin having excellent biofilm inhibiting ability of a strain.
본 발명의 또 다른 목적은 Streptococcus mutans 균주에 대하여 항균 효과를 갖는 모노라우린을 함유하는 항균 조성물을 제공하는데 있다.Another object of the present invention is to provide a method for producing Streptococcus mutans And an antimicrobial composition containing monolaurin having an antibacterial effect against a strain.
상기 목적을 달성하기 위하여, 본 발명은 모노라우린을 유효성분으로 함유하는 Streptococcus mutans의 바이오필름 형성 방지용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for inhibiting the formation of a biofilm of Streptococcus mutans containing monolaurin as an active ingredient.
본 발명은 또한, 모노라우린을 유효성분으로 함유하는 충치 예방 또는 치료용 의약조성물을 제공한다.The present invention also provides a pharmaceutical composition for preventing or treating cavities comprising monolaurin as an active ingredient.
본 발명은 또한, 모노라우린을 유효성분으로 함유하는 모노라우린을 함유하는 충치 예방용 의약외품을 제공한다.The present invention also provides a quasi-quasi-drug for preventing dental caries containing monolaurin containing monolaurin as an active ingredient.
본 발명은 또한, 모노라우린을 유효성분으로 함유하는 모노라우린을 함유하는 충치 예방용 건강기능식품을 제공한다.The present invention also provides a health functional food for preventing tooth decay containing monolaurin containing monolaurin as an active ingredient.
본 발명은 또한, 모노라우린을 유효성분으로 함유하는 Streptococcus mutans의 항균 조성물을 제공한다.The present invention also provides an antimicrobial composition of Streptococcus mutans containing monolaurin as an active ingredient.
본 발명의 조성물을 이용하면, Streptococcus mutans에 의한 치아우식을 효과적으로 예방할 수 있다. Use of the composition of the present invention can effectively prevent dental caries caused by Streptococcus mutans .
도 1은 S. mutans에 대한 모노라우린의 바이오필름 형성억제 효과를 나타낸 것이다.
도 2는 X. oryzae에 대한 모노라우린의 바이오필름 형성억제 효과를 나타낸 것이다.
도 3은 연속식 배양장치에서 S. mutans에 대한 모노라우린의 바이오필름 형성억제 효과를 나타낸 것이다.
도 4는 CFU(Colony Forming Unit) 측정법을 이용하여 S. mutans에 대한 모노라우린의 항균 효과를 나타낸 것이다. Figure 1 shows the inhibitory effect of monolaurin on S. aureus biofilm formation.
Figure 2 shows the inhibitory effect of monolaurate on X. oryzae biofilm formation.
3 shows the inhibitory effect of monolaurin on biofilm formation against S. mutans in a continuous culture apparatus.
FIG. 4 shows the antimicrobial effect of monolaurin against S. mutans using a CFU (Colony Forming Unit) assay.
본 발명에서는 모노라우린이 각 균주에 대한 바이오필름 형성 억제능을 가지는 것을 확인하였으며, 연속식 배양장치에서도 Streptococcus mutans에 대한 모노라우린의 바이오필름 형성을 억제하는 것을 확인하였다. In the present invention, it was confirmed that monolaurin had a biofilm formation inhibitory effect on each strain, and it was confirmed that monolaurin biofilm formation against Streptococcus mutans was inhibited even in a continuous culture apparatus.
따라서, 본 발명은 일 관점에서, 모노라우린을 유효성분으로 함유하는 Streptococcus mutans의 바이오필름 형성 방지용 조성물에 관한 것이다. Accordingly, in one aspect, the present invention relates to a composition for inhibiting the formation of a biofilm of Streptococcus mutans containing monolaurin as an active ingredient.
본 발명의 일 양태에서, 모노라우린은 0.45 ㎛ 구멍의 여과막을 이용하여 여과한 메탄올을 용매로 하여 4 g/L의 농도로 용해하였으며, 이를 1/2씩 연속 희석하여 사용하였다. 100 ㎕의 바이오필름 형성 배지에 5 ㎕ 처리하여 미생물의 바이오필름 형성억제 정도를 확인하였다. In one embodiment of the present invention, monolaurin was dissolved in methanol at a concentration of 4 g / L using methanol filtered through a 0.45 占 퐉 porous membrane, and this was diluted with 1/2 of the volume. 5 [mu] l was treated with 100 [mu] l of a biofilm formation medium to confirm the degree of inhibition of microbial biofilm formation.
다른 관점에서, 본 발명은 모노라우린을 유효성분으로 함유하는 충치 예방 또는 치료용 의약조성물에 관한 것이다.In another aspect, the present invention relates to a pharmaceutical composition for preventing or treating cavities comprising monolaurin as an active ingredient.
본 발명의 의약 조성물에 사용된 담체는 약제학적으로 허용되는 담체, 보조제 및 비히클을 포함하며 총괄적으로 "약제학적으로 허용되는 담체"라고 한다. 본 발명의 의약조성물에 사용될 수 있는 약제학적으로 허용되는 담체로는 이들로 한정되는 것은 아니지만 이온 교환, 알루미나, 알루미늄 스테아레이트, 레시틴, 혈청 단백질(예, 사람 혈청 알부민), 완충 물질(예, 여러 인산염, 글리신, 소르브산, 칼륨 소르베이트, 포화 식물성 지방산의 부분적인 글리세라이드 혼합물), 물, 염 또는 전해질(예, 프로타민 설페이트, 인산수소이나트륨, 인산수소칼륨, 염화나트륨 및 아연 염), 교질성 실리카, 마그네슘 트리실리케이트, 폴리비닐 피롤리돈, 셀룰로즈-계 기질, 폴리에틸렌 글리콜, 나트륨 카르복시메틸셀룰로즈, 폴리아릴레이트, 왁스, 폴리에틸렌-폴리옥시프로필렌-차단 중합체, 폴리에틸렌 글리콜 및 양모지 등이 포함된다.The carrier used in the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier, adjuvant and vehicle and is collectively referred to as a "pharmaceutically acceptable carrier ". Pharmaceutically acceptable carriers that can be used in the medicinal compositions of the present invention include, but are not limited to, ion exchange, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances Water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride and zinc salts), colloidal silicas such as glycerin, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, , Magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substrate, polyethylene glycol, sodium carboxymethyl cellulose, polyarylate, wax, polyethylene-polyoxypropylene-barrier polymer, polyethylene glycol and wool.
본 발명에 따른 의약 조성물의 투여 경로는 이들로 한정되는 것은 아니지만 구강, 정맥 내, 근육 내, 동맥 내, 골수 내, 경막 내, 심장 내, 경피, 피하, 복강 내, 비강 내, 장관, 국소, 설하 또는 직장이 포함된다. The route of administration of the pharmaceutical composition according to the present invention is not limited to the oral route, intravenous, intramuscular, intraarterial, intramedullary, intradermal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, Sublingual or rectal.
경구 및 비경구 투여가 바람직하다. 본원에 사용된 용어 "비경구"는 피하, 피 내, 정맥 내, 근육 내, 관절 내, 활액낭 내, 흉골 내, 경막 내, 병소 내 및 두개골 내 주사 또는 주입 기술을 포함한다. Oral and parenteral administration is preferred. The term "parenteral " as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
의약조성물은 멸균 주사용 수성 또는 유성 현탁액으로서 멸균 주사용 제제의 형태일 수 있다. 이 현탁액은 적합한 분산제 또는 습윤제(예, 트윈 80) 및 현탁화제를 사용하여 본 분야에 공지된 기술에 따라 제형될 수 있다. 멸균 주사용 제제는 또한 무독성의 비경구적으로 허용되는 희석제 또는 용매중의 멸균 주사용액 또는 현탁액(예, 1,3-부탄디올중의 용액)일 수 있다. 허용적으로 사용될 수 있는 비히클 및 용매로는 만니톨, 물, 링겔 용액 및 등장성 염화나트륨 용액이 있다. 또한, 멸균 불휘발성 오일이 통상적으로 용매 또는 현탁화 매질로서 사용된다. 이러한 목적을 위해, 합성 모노 또는 디글리세라이드를 포함하여 자극성이 적은 어떠한 불휘발성 오일도 사용할 수 있다. 올레산 및 이의 글리세라이드 유도체와 같은 지방산이 약제학적으로 허용되는 천연 오일(예, 올리브유 또는 피마자유), 특히 이들의 폴리옥시에틸화된 것과 마찬가지로 주사 제제에 유용하다.The pharmaceutical composition may be in the form of a sterile injectable preparation as a sterile injectable aqueous or oleaginous suspension. The suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (e. G., Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent (e.g., a solution in 1,3-butanediol). Vehicles and solvents that may be used tolerably include mannitol, water, a Ringgel solution and an isotonic sodium chloride solution. In addition, sterile, nonvolatile oils are conventionally employed as a solvent or suspending medium. For this purpose, any non-volatile oil with low irritation, including synthetic mono- or diglycerides, may be used. Fatty acids such as oleic acid and glyceride derivatives thereof are useful in injection formulations as well as pharmaceutically acceptable natural oils (e.g., olive oil or castor oil), especially those polyoxyethylated.
본 발명의 의약조성물은 이들로 한정되는 것은 아니지만 캡슐, 정제 및 수성 현탁액 및 용액을 포함하여 경구적으로 허용되는 어떠한 용량형으로도 경구 투여될 수 있다. 경구용 정제의 경우, 흔히 사용되는 담체로는 락토즈 및 옥수수 전분이 포함된다. 마그네슘 스테아레이트와 같은 윤활제가 또한 전형적으로 첨가된다. 캡슐형으로 경구 투여하는 경우 유용한 희석제로는 락토즈 및 건조된 옥수수 전분이 포함된다. 수성 현탁액이 경구 투여될 때 활성 성분은 유화제 및 현탁화제와 배합된다. 필요한 경우, 감미제 및/또는 풍미제 및/또는 착색제가 첨가될 수 있다.The pharmaceutical compositions of the present invention may be orally administered in any dosage form orally acceptable, including, but not limited to, capsules, tablets, and aqueous suspensions and solutions. In the case of oral tablets, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When the aqueous suspension is orally administered, the active ingredient is combined with an emulsifying agent and a suspending agent. If desired, sweetening and / or flavoring agents and / or coloring agents may be added.
본 발명의 의약조성물은 또한 직장 투여를 위한 좌제의 형태로 투여될 수 있다. 이들 조성물은 본 발명의 화합물을 실온에서 고형이지만 직장 온도에서는 액상인 적합한 비 자극성 부형제와 혼합하여 제조할 수 있다. 이러한 물질로는 이들로 한정되는 것은 아니지만 코코아 버터, 밀랍 및 폴리에틸렌 글리콜이 포함된다.The pharmaceutical compositions of the present invention may also be administered in the form of suppositories for rectal administration. These compositions may be prepared by admixing the compounds of the invention with suitable non-irritating excipients which are solid at room temperature but liquid at rectal temperature. Such materials include, but are not limited to, cocoa butter, beeswax, and polyethylene glycols.
본 발명에 따른 의약조성물의 경구 투여는 목적하는 치료가 국소 적용으로 접근이 용이한 부위 또는 기관과 관련이 있을 때 특히 유용하다. 피부에 국소적으로 적용하는 경우, 의약조성물은 담체에 현탁 또는 용해된 활성 성분을 함유한 적합한 연고로 제형되어야 한다. 본 발명의 화합물을 국소 투여하기 위한 담체로는 이들로 한정되는 것은 아니지만 광유, 유동 파라핀, 백색 와셀린, 프로필렌 글리콜, 폴리옥시에틸렌, 폴리옥시프로필렌 화합물, 유화 왁스 및 물이 포함된다. 다른 방도로서, 의약조성물은 담체에 현탁 또는 용해된 활성 화합물을 함유한 적합한 로션 또는 크림으로 제형 될 수 있다. 적합한 담체로는 이들로 한정되는 것은 아니지만 광유, 솔비탄 모노스테아레이트, 폴리솔베이트 60, 세틸 에스테르 왁스, 세테아릴 알코올, 2-옥틸도데카놀, 벤질 알코올 및 물이 포함된다. 본 발명의 의약조성물은 또한 직장 좌제에 의해 또한 적합한 관장제로 하부 장관으로 국소 적용할 수 있다. 국소 적용된 경피 패치가 또한 본 발명에 포함된다.Oral administration of a pharmaceutical composition according to the present invention is particularly useful when the desired treatment is associated with a site or organ that is accessible by topical application. When topically applied to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active ingredient suspended or dissolved in the carrier. Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid paraffin, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and water. Alternatively, the pharmaceutical composition may be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate,
본 발명의 의약조성물은 비 내 에어로졸 또는 흡입에 의해 투여할 수 있다. 이러한 조성물은 약제의 분야에 잘 알려진 기술에 따라 제조하며 벤질 알코올 또는 다른 적합한 보존제, 생체이용률을 증강시키기 위한 흡수 촉진제, 플루오로카본 및/또는 기타 본 분야에 알려진 가용화제 또는 분산제를 사용하여 염수중의 용액으로서 제조할 수 있다.The pharmaceutical composition of the present invention can be administered by non-aerosol or by inhalation. Such compositions are prepared according to techniques well known in the art of pharmacy and can be prepared using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other solubilizing or dispersing agents known in the art, Solution.
특정 환자에 대한 특정 유효량은 사용된 특정 화합물의 활성, 연령, 체중, 일반적인 건강, 성별, 규정식, 투여시간, 투여경로, 배출율, 약물 배합 및 예방 또는 치료될 특정 질환의 중증을 포함한 여러 요인에 따라 변할 수 있음은 이해될 것이다. 본 발명에 따른 의약 조성물은 환제, 당의정, 캡슐, 액제, 겔, 시럽, 슬러리, 현탁제로 제형 될 수 있다. The specific effective amount for a particular patient will depend on a variety of factors including the activity of the particular compound employed, age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease It will be appreciated that it can vary. The pharmaceutical composition according to the present invention can be formulated into pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions.
본 발명에 따른 의약 조성물을 어류의 피하세포에 투입할 경우 새낭 또는 소화관에 투여할 수 있다. 주사는 근육조직내의 근육세포 또는 다른 세포에 주사할 수 있으며 복강 내의 내장세포에 주사할 수 있다.When the medicinal composition according to the present invention is injected into subcutaneous cells of a fish, it can be administered to a dacryocyst or digestive tract. Injection can be injected into muscle cells or other cells within the muscle tissue and injected into the intestinal cells in the abdominal cavity.
바람직한 양태로서, 구강 내 투여를 위한 의약 조성물은 고체상의 부형제와 함께 활성 성분을 혼합함으로써 제조할 수 있으며 정제 또는 당의정 형태로 제조하기 위해 과립형태로 제조할 수 있다. 적합한 부형제로는 락토스, 수크로스, 만니톨 및 소르비톨과 같은 슈가 형태 또는 옥수수, 밀가루, 쌀, 감자 또는 다른 식물로부터 전분, 메틸 셀룰로스, 하이드로시프로필메틸-셀룰로스 또는 나트륨 카복시메틸셀룰로스와 같은 셀룰로스, 아라빅 검, 타가칸쓰 검을 포함하는 검류와 같은 카보하이드레이트 또는 젤라틴, 콜라겐과 같은 단백질 필러를 사용할 수 있다. 필요한 경우에는, 교차결합 된 폴리비닐피롤리돈, 아가 및 알긴산 또는 나트륨 알긴산과 같은 각각의 염 형태의 붕해제 또는 용해제를 첨가할 수 있다.In a preferred embodiment, the pharmaceutical compositions for oral administration can be prepared by mixing the active ingredients together with solid excipients and may be prepared in the form of granules for preparation in the form of tablets or dragees. Suitable excipients include sugars such as lactose, sucrose, mannitol and sorbitol or starch from corn, wheat flour, rice, potato or other plants, celluloses such as methylcellulose, hydrocipylmethylcellulose or sodium carboxymethylcellulose, Carbohydrates such as gums containing gum and tagacan gum, or protein fillers such as gelatin and collagen can be used. If necessary, disintegrating or solubilizing agents in the form of respective salts such as cross-linked polyvinylpyrrolidone, agar and alginic acid or sodium alginic acid may be added.
바람직한 양태로서, 비경구적 투여의 경우 본 발명의 의약 조성물은 수용성 용액으로 제조할 수 있다. 바람직하게는, 한스 용액(Hank's solution), 링거 용액(Ringer's solution) 또는 물리적으로 완충된 염수와 같은 물리적으로 적절한 완충용액을 사용할 수 있다. 수용성 주입(injection) 현탁액은 소디움 카복시메틸 셀룰로스, 소르비톨 또는 덱스트란과 같이 현탁액의 점도를 증가시킬 수 있는 기질을 첨가할 수 있다. 덧붙여서, 활성 성분의 현탁액은 적합한 유질의 주입 현탁액(oily injection suspensions)으로 제조될 수 있다. 적합한 친지성 용매 또는 담체는 참기름과 같은 지방산 또는 에틸 올레이트, 트리글리세라이드 또는 리포솜과 같은 합성 지방산 에스테르를 포함한다. 복수양이온성 비지질 아미노 폴리머(polycationic amino polymers)도 운반체로서 사용될 수 있다. 임의로, 현탁액은 화합물의 용해도를 증가시키고 고농도의 용액을 제조하기 위해 적합한 안정화제 또는 약제를 사용할 수 있다.In a preferred embodiment, for parenteral administration, the pharmaceutical composition of the present invention can be prepared as a water-soluble solution. Preferably, physically suitable buffer solutions such as Hank's solution, Ringer's solution or physically buffered saline can be used. Aqueous injection suspensions may contain a substrate capable of increasing the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol or dextran. In addition, suspensions of the active ingredient may be prepared in suitable oily injection suspensions. Suitable lipophilic solvents or carriers include fatty acids such as sesame oil or synthetic fatty acid esters such as ethyl oleate, triglycerides or liposomes. Polycationic amino polymers can also be used as carriers. Optionally, the suspension may employ a suitable stabilizing agent or agent to increase the solubility of the compound and to produce a high concentration of solution.
이상과 같은 안정화제, 완충제 혹은 흡착방지제를 가하여 본 발명 제제를 조제할 수 있지만, 특히 의료용 또는 동물약용 주사제로서 이용하는 경우는 삼투압비로서 허용되는 삼투압비는 1 내지 2가 좋다. 삼투압비는 약제화시에 염화나트륨의 증감에 의해 조제할 수 있다. The formulation of the present invention can be prepared by adding a stabilizer, a buffer or an anti-adsorption agent as described above. In particular, when used as an injection for medical use or an animal medicine, an osmotic pressure ratio of 1 to 2 is acceptable as an osmotic pressure ratio. The osmotic pressure ratio can be adjusted by increasing or decreasing sodium chloride during the chemical reduction.
또 다른 관점에서, 본 발명은 모노라우린을 함유하는 충치 예방용 의약외품에 관한 것이다.In another aspect, the present invention relates to a quasi-drug for preventing tooth decay containing monolaurin.
본 발명의 의약외품은 구강청결제, 치약 등을 들 수 있다. The quasi-drugs of the present invention include oral cleansers and toothpastes.
또 다른 관점에서, 본 발명은 모노라우린을 함유하는 기능성 식품에 관한 것이다.In another aspect, the present invention relates to a functional food containing monolaurin.
본 발명의 기능성 식품은 충치 예방을 위한 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 기능성 식품은, 예를 들어, 각종 식품류, 캔디, 초콜릿, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.The functional food of the present invention can be used variously for medicines, foods and beverages for prevention of tooth decay. The functional food of the present invention can be used in the form of powder, granule, tablet, capsule or beverage, for example, various foods, candy, chocolate, beverage, gum, tea, vitamin complex and health supplement.
본 발명의 상기 추출물은 충치 예방을 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 일반적으로 본 발명의 건강 기능 식품 조성물은 전체 식품 중량의 0.01 내지 50 중량 %, 바람직하게는 0.1 내지 20 중량 %로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.The extract of the present invention can be added to foods or beverages for the purpose of preventing tooth decay. At this time, the amount of the above extract in the food or beverage may generally be 0.01 to 50% by weight, preferably 0.1 to 20% by weight, of the total food weight of the health functional food composition of the present invention, In a proportion of 0.02 to 10 g, preferably 0.3 to 1 g.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 수크로스 등의 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health beverage composition of the present invention has no particular limitation on the liquid ingredient other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as polysaccharides such as disaccharides such as glucose and fructose such as maltose and sucrose, and polysaccharides such as dextrin, cyclodextrin and the like. And sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
또 다른 관점에서, 본 발명은 모노라우린을 유효성분으로 함유하는 Streptococcus mutans의 항균 조성물에 관한 것이다.In another aspect, the present invention relates to an antimicrobial composition of Streptococcus mutans containing monolaurin as an active ingredient.
본 발명의 항균 조성물은 Streptococcus mutans 균주에 대하여 90% 이상의 억제 효과를 나타내고 농도 의존적으로 항균 효과가 우수한 것을 확인하였다.The antimicrobial composition of the present invention comprises Streptococcus mutans It was confirmed that the strain showed an inhibitory effect of 90% or more on the strain and that the antimicrobial effect was excellent in a concentration-dependent manner.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these examples are for illustrative purposes only and that the scope of the present invention is not construed as being limited by these examples.
실시예 1: 모노라우린Example 1: Monolaurin
본 실시예에서 사용한 모노라우린(Monolaurin, 1-lauroyl-rac-glycerol)은 Sigma-Aldrich에서 구입하였으며 정보는 다음과 같다.The monolaurin (1-lauroyl- rac -glycerol) used in this example was purchased from Sigma-Aldrich and the information is as follows.
모노라우린 4 g을 0.45 ㎛ 구멍의 여과막을 이용하여 여과한 메탄올 1 L에 용해시켜 준비하였으며, 시료 5 ㎕ 처리하여 미생물의 생장과 바이오필름 형성억제 정도를 확인하였다. 4 g of monolaurin was prepared by dissolving in 1 L of methanol filtered through a 0.45 ㎛ pore filter, and treated with 5 ㎕ of sample to confirm microbial growth and inhibition of biofilm formation.
실시예Example 2: 2: S. S. mutansmutans 에on 대한 About 모노라우린의Monolaurin 바이오필름 형성억제 효과 Biofilm formation inhibitory effect
본 실시예에서 사용한 S. mutans는 LG생활건강 기술연구원에서 분양받아 사용하였다. The S. mutans used in this example was purchased from LG H & H Research Institute.
-80℃에서 보관되어 있던 S. mutans 균주를 활발한 생육 상태로 만들기 위하여, BHI 고체배지에 도말한 후, 37℃ 에서 2일간 배양하였다. 배양된 균주는 5 ml의 BHI 액체배지(BactoTM)에 접종한 후, test tube에서 37℃로 shaking 없이 1일간 배양한 다음, 배양액의 세포 농도를 Abs600으로 측정하였다. S. mutans stored at -80 ° C The strain was plated on a BHI solid medium and incubated at 37 ° C for 2 days to make the strain vigorous. The cultured strain was inoculated into 5 ml of BHI liquid medium (Bacto ™ ), cultured in a test tube at 37 ° C for 1 day without shaking, and the cell concentration of the culture was measured as Abs600.
BHI 액체배지의 조성은 표 2에 나타내었다. The composition of the BHI liquid medium is shown in Table 2.
96웰의 PVC 마이크로플레이트에 BHI + 1% Sucrose 배지를 100 μl씩 분주하고, 실시예 1에서 제조한 모노라우린 시료를 5 ㎕씩 추가로 분주하였다. 상기 분주된 각 웰에 BHI 배지에서 배양된 S. mutans 균주를 세포농도 Abs600=0.05가 되도록 접종하고, 37℃에서 24시간 동안 배양하였다.100 μl of BHI + 1% sucrose medium was dispensed into 96-well PVC microplates, and 5 μl of the monolaurin sample prepared in Example 1 was further added. In each of the dispensed wells, S. mutans cultured in BHI medium The strain was inoculated at a cell concentration of Abs600 = 0.05 and cultured at 37 DEG C for 24 hours.
BHI + 1% Sucrose 배지의 조성은 표 3에 나타내었다. The composition of BHI + 1% sucrose medium is shown in Table 3.
배양액을 제거한 후, 물로 3번 세척하고, 1% crystal violet 용액 100 μl를 각각의 웰에 넣고 15분간 상온에서 정치하여 반응시켰다. 반응이 끝난 용액을 제거하고 물로 3번 부드럽게 세척한 후, 95% 에탄올 100 μl를 각각의 웰에 넣고 15분간 정치시킨 후, Abs595에서 마이크로플레이트 리더로 바이오필름의 형성 정도를 측정하였다. After removing the culture medium, the cells were washed three times with water, and 100 μl of a 1% crystal violet solution was added to each well. The mixture was allowed to stand at room temperature for 15 minutes and reacted. After the reaction was completed, the solution was washed gently with water three times. Then, 100 μl of 95% ethanol was added to each well, allowed to stand for 15 minutes, and then the degree of biofilm formation was measured with Abs595 using a microplate reader.
그 결과, 도 1에 나타난 바와 같이, 모노라우린을 메탄올에 용해시켜 처리한 경우 S. mutans 균주가 생산하는 바이오필름의 형성을 억제하는 효과를 나타내었으며, 약 48 mg/L의 농도에서 66%의 억제를 나타내고 농도 의존적으로 강력하게 바이오필름 형성을 억제하는 것을 확인하였다.As a result, as shown in Fig. 1, when monolaurin was dissolved in methanol and treated, S. mutans Inhibited the formation of the biofilm produced by the strain, showed a 66% inhibition at a concentration of about 48 mg / L and inhibited the formation of biofilm in a concentration-dependent manner.
실시예Example 3: 3: X. X. oryzaeoryzae 에on 대한 About 모노라우린의Monolaurin 바이오필름 형성억제 효과 Biofilm formation inhibitory effect
본 실시예에서 사용한 X. oryzae (KACC 10331)는 농촌진흥청 농업유전자원정보센터에서 분양받아 사용하였다. The X. oryzae (KACC 10331) was used by the Rural Development Administration at the Agricultural Genetic Resources Information Center.
-80℃에서 보관되어 있던 X. oryzae 균주를 고체배양 배지인 YGC 배지에서 도말한 후, 28℃ 에서 2일간 배양하여 활발한 생육상태 균주로 배양하였다. 한천을 이용한 고형배지인 YGC 배지의 조성은 표 4와 같다. X. oryzae stored at -80 < RTI ID = 0.0 > The strain was plated in a solid culture medium, YGC medium, and cultured at 28 ° C. for 2 days to grow into an active growth strain. The composition of the YGC medium, which is a solid medium using agar, is shown in Table 4.
YGC 배지에서 배양된 X. oryzae 균주는 액체 배지인 210 배지 5 ml에 접종한 후, 28℃, 250 rpm에서 2일간 배양하였다. 배양에 사용된 210 배지의 조성은 표 5에 나타내었다.The X. oryzae strain cultivated in YGC medium was inoculated into 5 ml of 210 medium, which was then cultured at 28 ° C and 250 rpm for 2 days. The composition of the 210 medium used for the cultivation is shown in Table 5.
210 배지에서 배양된 X. oryzae 균주의 바이오필름 형성을 모노라우린이 억제하는지 확인하기 위하여, 바이오필름 형성용 배지인 XOM2 배지를 사용하였다. XOM2 배지의 조성은 표 6에 나타내었다. X. oryzae cultured on 210 medium To confirm whether monolaurin inhibited the formation of the biofilm of the strain, XOM2 medium, which is a biofilm formation medium, was used. The composition of the XOM2 medium is shown in Table 6.
96웰의 PVC 마이크로플레이트에 XOM2 배지를 100 μl씩 분주하고, 실시예 1에서 제조한 모노라우린 시료를 5 ㎕씩 추가로 분주하였다. 상기 분주된 각 웰에 210 배지에서 배양된 X. oryzae 균주를 세포농도 Abs600=0.05가 되도록 접종하고, 28℃에서 24시간 동안 배양하였다.100 [mu] l of XOM2 medium was dispensed into a 96-well PVC microplate, and 5 [mu] l of the monolaurin sample prepared in Example 1 was further added. To each of the divided wells was added X. oryzae The strain was inoculated at a cell concentration of Abs600 = 0.05, and cultured at 28 DEG C for 24 hours.
배양액을 제거한 후, 물로 3번 세척하고, 1% crystal violet 용액 100 μl를 각각의 웰에 넣고 15분간 상온에서 정치하여 반응시켰다. 반응이 끝난 용액을 제거하고 물로 3번 부드럽게 세척한 후, 95% 에탄올 100 μl를 각각의 웰에 넣고 15분간 정치시킨 후, Abs595에서 마이크로플레이트 리더로 바이오필름의 형성정도를 측정하였다.After removing the culture medium, the cells were washed three times with water, and 100 μl of a 1% crystal violet solution was added to each well. The mixture was allowed to stand at room temperature for 15 minutes and reacted. After the reaction was completed, the solution was washed gently with water three times. Then, 100 μl of 95% ethanol was added to each well, allowed to stand for 15 minutes, and then the degree of biofilm formation was measured with Abs595 using a microplate reader.
그 결과, 도 2에 나타난 바와 같이, 모노라우린을 메탄올에 용해시켜 처리한 경우 X. oryzae 균주가 생산하는 바이오필름의 형성을 억제하는 효과를 나타내었으며, 약 48 mg/L의 농도에서 95% 이상의 강력한 억제효과를 나타내는 것을 확인하였다.As a result, as shown in Fig. 2, when monolaurin was dissolved in methanol and treated, X. oryzae Inhibited the formation of the biofilm produced by the strain and showed a strong inhibitory effect of 95% or more at a concentration of about 48 mg / L.
실시예Example 4: 연속식 배양장치에서 4: In the continuous culture apparatus S. S. mutansmutans 에on 대한 About 모노라우린의Monolaurin 바이오필름 형성억제 효과 Biofilm formation inhibitory effect
본 실시예에서 사용한 S. mutans는 LG생활건강 기술연구원에서 분양받아 사용하였다. The S. mutans used in this example was purchased from LG H & H Research Institute.
-80℃에서 보관되어 있던 S. mutans 균주를 활발한 생육 상태로 만들기 위하여, BHI 고체배지에 도말한 후, 37℃ 에서 2일간 배양하였다. 배양된 균주는 5 ml의 BHI 액체배지(BactoTM)에 접종한 후, test tube에서 37℃로 shaking 없이 1일간 배양한 다음, 배양액의 세포 농도를 Abs600으로 측정하였다. S. mutans stored at -80 ° C The strain was plated on a BHI solid medium and incubated at 37 ° C for 2 days to make the strain vigorous. The cultured strain was inoculated into 5 ml of BHI liquid medium (Bacto ™ ), cultured in a test tube at 37 ° C for 1 day without shaking, and the cell concentration of the culture was measured as Abs600.
세포 농도 Abs600=0.15가 되도록 희석한 후, 실시예 1에서 제조한 모노라우린 시료 350 ㎕을 분주하였으며, 1시간 동안 뒤집어서 정치하였다. 다시 원상태로 뒤집은 후, 13 ml/h의 유속으로 24시간 동안 바이오필름 형성 변화를 현미경을 이용하여 관찰한 결과를 도 3에 나타내었다. After diluting to a cell concentration of Abs600 = 0.15, 350 [mu] l of the monolaurin sample prepared in Example 1 was dispensed and left to stand for 1 hour. 3, the change in biofilm formation was observed under a microscope for 24 hours at a flow rate of 13 ml / h.
도 3A는 1시간 동안 뒤집어서 정치한 다음 원상태로 뒤집은 상태를 현미경으로 측정한 것이며, 도 3B는 원상태로 뒤집은 다음 13 ml/h의 유속으로 24시간이 지난 후의 상태를 현미경으로 측정한 결과이다.FIG. 3A is a microscopic chart of a state where the sample was inverted for one hour and then inverted to a normal state. FIG. 3B is a result of microscopic measurement of the state after 24 hours at a flow rate of 13 ml / h after reversing the original state.
도 3에 나타난 바와 같이, 연속식 배양장치에서 S. mutans의 바이오필름 형성이 억제되는 것을 확인하였으며 초기 부착 시에는 영향이 미비하지만(도 3A), 24시간 후 모노라우린을 처리한 S. mutans의 바이오필름 형성이 처리하지 않은 대조군과 비교하여 바이오필름의 성숙에 저해 받았음을 알 수 있었다. 따라서 연속식 배양장치를 통하여 모노라우린은 S. mutans의 바이오필름 형성의 부착, 성숙, 분해로 이루어지는 3단계 중 바이오필름의 성숙을 저해하는 효과가 있는 것을 확인할 수 있었다. As shown in Fig. 3, it was confirmed that the biofilm formation of S. mutans was inhibited in the continuous culture apparatus, and there was little effect at the initial attachment (Fig. 3A), but the S. mutans treated with monolaurin after 24 hours Was inhibited by the maturation of the biofilm compared to the control without biofilm formation. Therefore, it was confirmed that monolaurin has an effect of inhibiting the maturation of the biofilm during the three steps of adhesion, maturation, and degradation of the biofilm formation of S. mutans through the continuous culture apparatus.
실시예Example 5: 5: S. S. mutansmutans 에on 대한 About 모노라우린의Monolaurin 항균 효과 Antimicrobial effect
본 실시예에서 사용한 S. mutans는 LG생활건강 기술연구원에서 분양받아 사용하였다. The S. mutans used in this example was purchased from LG H & H Research Institute.
-80℃에서 보관되어 있던 S. mutans 균주를 활발한 생육 상태로 만들기 위하여, BHI 고체배지에 도말한 후, 37℃ 에서 2일간 배양하였다. 배양된 균주는 5 ml의 BHI 액체배지(BactoTM)에 접종한 후, test tube에서 37℃로 shaking 없이 1일간 배양한 다음, 배양액의 세포 농도를 Abs600으로 측정하였다. S. mutans stored at -80 ° C The strain was plated on a BHI solid medium and incubated at 37 ° C for 2 days to make the strain vigorous. The cultured strain was inoculated into 5 ml of BHI liquid medium (Bacto ™ ), cultured in a test tube at 37 ° C for 1 day without shaking, and the cell concentration of the culture was measured as Abs600.
시험관에 BHI + 1% Sucrose 배지를 2 ml씩 분주하고, BHI 배지에서 배양된 S. mutans 균주를 세포농도 Abs600=0.05가 되도록 접종하고, 37℃에서 shaking 없이 24시간 동안 배양하였다. 이를 연속 희석하여 BHI 한천 배지에 도말한 후, 37℃에서 2일간 배양하였으며, 형성된 단일 군집의 숫자를 세어 S. mutans에 대한 모노라우린의 항균 효과를 확인하였다. 2 ml of BHI + 1% Sucrose medium was added to each test tube, and S. mutans cultured in BHI medium The strain was inoculated at a cell concentration of Abs600 = 0.05, and cultured at 37 DEG C for 24 hours without shaking. This was serially diluted and plated on BHI agar medium, incubated at 37 ° C for 2 days, and the number of single clusters formed was counted to confirm the antimicrobial effect of monolaurin against S. mutans .
그 결과, 도 4에 나타난 바와 같이, 모노라우린은 S. mutans에 대하여 12 mg/L의 농도에서 90% 이상의 억제 효과를 나타내고 농도 의존적으로 항균 효과가 우수한 것을 확인하였다.As a result, as shown in FIG. 4, monolaurin exhibited an inhibitory effect of 90% or more at a concentration of 12 mg / L against S. mutans , and it was confirmed that the monolaurin had an antimicrobial effect in a concentration-dependent manner.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereby. something to do. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.
Claims (5)
A composition for inhibiting the formation of a biofilm of Streptococcus mutans containing monolaurin as an active ingredient.
A pharmaceutical composition for preventing or treating cavities comprising monolaurin as an active ingredient.
Quasi-drug for preventing tooth decay containing monolaurin as an active ingredient.
A health functional food for preventing tooth decay containing monolaurin as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160037496A KR20170111640A (en) | 2016-03-29 | 2016-03-29 | Composition Containing Monolaurin for Preventing Biofilm Formation of Streptococcus mutans |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160037496A KR20170111640A (en) | 2016-03-29 | 2016-03-29 | Composition Containing Monolaurin for Preventing Biofilm Formation of Streptococcus mutans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170111640A true KR20170111640A (en) | 2017-10-12 |
Family
ID=60141473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160037496A KR20170111640A (en) | 2016-03-29 | 2016-03-29 | Composition Containing Monolaurin for Preventing Biofilm Formation of Streptococcus mutans |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20170111640A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020003197A3 (en) * | 2018-06-29 | 2020-05-07 | 3M Innovative Properties Company | Orthodontic articles prepared using a polycarbonate diol, polymerizable compositions, and methods of making the articles |
| JP2020075887A (en) * | 2018-11-08 | 2020-05-21 | シャボン玉石けん株式会社 | Biofilm removers and methods for removing biofilms |
| US11945900B2 (en) | 2018-06-29 | 2024-04-02 | 3M Innovative Properties Company | Orthodontic articles prepared using a polycarbonate diol, polymerizable compositions, and methods of making the articles |
-
2016
- 2016-03-29 KR KR1020160037496A patent/KR20170111640A/en active Search and Examination
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020003197A3 (en) * | 2018-06-29 | 2020-05-07 | 3M Innovative Properties Company | Orthodontic articles prepared using a polycarbonate diol, polymerizable compositions, and methods of making the articles |
| US11945900B2 (en) | 2018-06-29 | 2024-04-02 | 3M Innovative Properties Company | Orthodontic articles prepared using a polycarbonate diol, polymerizable compositions, and methods of making the articles |
| JP2020075887A (en) * | 2018-11-08 | 2020-05-21 | シャボン玉石けん株式会社 | Biofilm removers and methods for removing biofilms |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6387467B2 (en) | Mangosteen extract or composition for preventing or ameliorating periodontal disease comprising alpha and gamma mangosteen as active ingredients | |
| KR102015237B1 (en) | Composition for oral use | |
| WO2005091937A2 (en) | Compositions useful for the treatment of microbial infections | |
| KR20170111640A (en) | Composition Containing Monolaurin for Preventing Biofilm Formation of Streptococcus mutans | |
| CN109503510B (en) | Antibacterial thiazole compound for preventing caries and preparation method thereof | |
| KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
| KR101379318B1 (en) | Novel analogues of antibacterial peptide derived from Styela clava and the use thereof | |
| US20230372232A1 (en) | Oral care composition comprising sweet potato-derived potato syrup or supernatant of potato syrup | |
| KR101764304B1 (en) | Composition for Preveting Biofilm Formation Containing Enzyme Treated Extract of Clove | |
| KR101833435B1 (en) | Composition Containing Monolaurin for Preventing Biofilm Formation of Xanthomonas oryzae | |
| KR20170107237A (en) | Composition for Preventing Biofilm Formation of Streptococcus mutans Containing Ethanol Extract of Clove | |
| KR101735895B1 (en) | Composition for inhibiting oral bacteria adhesion comprising five-carbon sugars and xylitol | |
| KR101722230B1 (en) | Composition for Preveting Biofilm Formation Containing Extract of Clove | |
| KR101776696B1 (en) | Isosorbide derivatives having anti-microbial activity and anti-microbial composition composition the same | |
| KR101764303B1 (en) | Composition for Preventing Biofilm Formation Containing Enzyme Treated Extract of licorice | |
| KR20150044270A (en) | Composition for Preveting Biofilm Formation Containing Extract of licorice | |
| KR20150068713A (en) | Composition for Preveting Biofilm Formation Containing Enzyme Treated Extract of Clove | |
| KR20170107239A (en) | Composition for Preventing Biofilm Formation Containing Ethanol Extract of licorice | |
| KR20200027663A (en) | Composition for preventing or treating oral disease comprising sulfated polysaccharide as an effective ingredient | |
| KR102603281B1 (en) | Novel peptide derived from Hylin a1 peptide and uses thereof | |
| KR20170107238A (en) | Composition for Preventing Biofilm Formation of Yersinia enterocolitica Containing Ethanol Extract of Clove | |
| KR102608336B1 (en) | Novel peptide derived from pep27 peptide and uses thereof | |
| JP7433125B2 (en) | Oral antibacterial agent | |
| KR101799984B1 (en) | Composition for Preveting Biofilm Formation Containing Extract of licorice | |
| KR101791407B1 (en) | Composition for Skin Whitening Comprising Stipitalide as Active Ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment |